Oncorena AB is a Swedish pharmaceutical company focused on developing a breakthrough treatment for metastatic renal cancer, leveraging the anti-tumor activity of its drug candidate ONC175 (orellanine)
Oncorena AB is a Swedish pharmaceutical company focused on developing a breakthrough treatment for metastatic renal cancer, leveraging the anti-tumor activity of its drug candidate ONC175 (orellanine).